Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.36
COV's Cash to Debt is ranked higher than
58% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. COV: 0.36 )
COV' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.36

Equity to Asset 0.50
COV's Equity to Asset is ranked higher than
63% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. COV: 0.50 )
COV' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.61
Current: 0.5

0.36
0.61
Interest Coverage 9.76
COV's Interest Coverage is ranked higher than
58% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. COV: 9.76 )
COV' s 10-Year Interest Coverage Range
Min: 2.33   Max: 12.44
Current: 9.76

2.33
12.44
F-Score: 7
Z-Score: 3.89
M-Score: -2.62
WACC vs ROIC
2.13%
15.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.70
COV's Operating margin (%) is ranked higher than
90% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. COV: 19.70 )
COV' s 10-Year Operating margin (%) Range
Min: 4.31   Max: 26.05
Current: 19.7

4.31
26.05
Net-margin (%) 16.58
COV's Net-margin (%) is ranked higher than
93% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. COV: 16.58 )
COV' s 10-Year Net-margin (%) Range
Min: -3.26   Max: 19.34
Current: 16.58

-3.26
19.34
ROE (%) 17.99
COV's ROE (%) is ranked higher than
92% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. COV: 17.99 )
COV' s 10-Year ROE (%) Range
Min: -4.32   Max: 20.42
Current: 17.99

-4.32
20.42
ROA (%) 8.73
COV's ROA (%) is ranked higher than
87% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. COV: 8.73 )
COV' s 10-Year ROA (%) Range
Min: -2.05   Max: 9.3
Current: 8.73

-2.05
9.3
ROC (Joel Greenblatt) (%) 54.83
COV's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. COV: 54.83 )
COV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.46   Max: 94.45
Current: 54.83

9.46
94.45
Revenue Growth (3Y)(%) 0.10
COV's Revenue Growth (3Y)(%) is ranked higher than
66% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. COV: 0.10 )
COV' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 9.2
Current: 0.1

0
9.2
EBITDA Growth (3Y)(%) -2.00
COV's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 225 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. COV: -2.00 )
COV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 50.9
Current: -2

0
50.9
EPS Growth (3Y)(%) -1.20
COV's EPS Growth (3Y)(%) is ranked higher than
69% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. COV: -1.20 )
COV' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 21.9
Current: -1.2

0
21.9
» COV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

COV Guru Trades in Q1 2014

Louis Moore Bacon 6,022 sh (New)
Paul Tudor Jones 289,467 sh (New)
Joel Greenblatt 3,746 sh (New)
Jeremy Grantham 2,103,588 sh (+71.85%)
HOTCHKIS & WILEY 788,400 sh (+20.00%)
Pioneer Investments 3,131,476 sh (+3.77%)
Bill Nygren 2,708,000 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Robert Olstein 94,500 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Ronald Muhlenkamp 181,455 sh (-0.10%)
Private Capital 243,820 sh (-0.30%)
Donald Yacktman 1,784,825 sh (-0.31%)
John Keeley 43,770 sh (-1.68%)
First Pacific Advisors 5,184,500 sh (-3.04%)
Dodge & Cox 101,517 sh (-8.80%)
Manning & Napier Advisors, Inc 71,870 sh (-11.02%)
Mario Gabelli 543,560 sh (-12.63%)
Ray Dalio 47,058 sh (-41.80%)
Steven Cohen 6,418 sh (-80.02%)
» More
Q2 2014

COV Guru Trades in Q2 2014

Eric Mindich 446,000 sh (New)
John Paulson 7,000,000 sh (New)
George Soros 227,000 sh (New)
Louis Moore Bacon 126,022 sh (+1992.69%)
Jeremy Grantham 2,776,488 sh (+31.99%)
Mario Gabelli 637,530 sh (+17.29%)
Ronald Muhlenkamp 182,180 sh (+0.40%)
HOTCHKIS & WILEY 788,700 sh (+0.04%)
Jean-Marie Eveillard 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Donald Yacktman Sold Out
Manning & Napier Advisors, Inc Sold Out
Yacktman Fund Sold Out
Robert Olstein Sold Out
Yacktman Focused Fund Sold Out
Private Capital 238,715 sh (-2.09%)
Steven Romick 4,559,929 sh (-6.01%)
John Keeley 40,840 sh (-6.69%)
First Pacific Advisors 4,822,800 sh (-6.98%)
Dodge & Cox 92,017 sh (-9.36%)
Pioneer Investments 1,818,973 sh (-41.91%)
Bill Nygren 160,000 sh (-94.09%)
Paul Tudor Jones 7,416 sh (-97.44%)
» More
Q3 2014

COV Guru Trades in Q3 2014

Steven Cohen 45,000 sh (New)
Paul Singer 502,653 sh (New)
David Abrams 2,620,000 sh (New)
Eric Mindich 3,881,000 sh (+770.18%)
Jeremy Grantham 12,981,012 sh (+367.53%)
John Paulson 12,595,000 sh (+79.93%)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Steven Romick 4,559,929 sh (unchged)
Bill Nygren 160,000 sh (unchged)
Pioneer Investments 1,770,893 sh (unchged)
John Keeley 40,840 sh (unchged)
Ronald Muhlenkamp 182,180 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors 4,774,600 sh (-1.00%)
Dodge & Cox 89,017 sh (-3.26%)
HOTCHKIS & WILEY 727,700 sh (-7.73%)
Mario Gabelli 462,251 sh (-27.49%)
Private Capital 157,828 sh (-33.88%)
Paul Tudor Jones 3,900 sh (-47.41%)
» More
Q4 2014

COV Guru Trades in Q4 2014

George Soros 197,768 sh (New)
John Burbank 5,094 sh (New)
David Einhorn 851,341 sh (New)
Eric Mindich 5,481,800 sh (+41.25%)
HOTCHKIS & WILEY 935,100 sh (+28.50%)
Pioneer Investments 2,008,046 sh (+13.39%)
David Abrams 2,950,000 sh (+12.60%)
Steven Cohen 50,000 sh (+11.11%)
Steven Romick 4,651,129 sh (+2.00%)
First Pacific Advisors 4,861,900 sh (+1.83%)
John Keeley 40,860 sh (+0.05%)
Jean-Marie Eveillard 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Paul Tudor Jones Sold Out
Paul Singer Sold Out
Bill Nygren Sold Out
Ronald Muhlenkamp 181,650 sh (-0.29%)
Private Capital 152,848 sh (-3.16%)
Dodge & Cox 78,686 sh (-11.61%)
John Paulson 10,047,500 sh (-20.23%)
Mario Gabelli 359,176 sh (-22.30%)
Jeremy Grantham 9,819,037 sh (-24.36%)
» More
» Details

Insider Trades

Latest Guru Trades with COV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Covidien PLC

Steven Romick's Top Five Stocks
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.50
COV's P/E(ttm) is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.70 vs. COV: 27.50 )
COV' s 10-Year P/E(ttm) Range
Min: 10.07   Max: 27.81
Current: 27.5

10.07
27.81
Forward P/E 22.22
COV's Forward P/E is ranked higher than
83% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.56 vs. COV: 22.22 )
N/A
PE(NRI) 27.40
COV's PE(NRI) is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.40 vs. COV: 27.40 )
COV' s 10-Year PE(NRI) Range
Min: 9.85   Max: 27.81
Current: 27.4

9.85
27.81
P/B 4.66
COV's P/B is ranked higher than
61% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. COV: 4.66 )
COV' s 10-Year P/B Range
Min: 1.64   Max: 4.72
Current: 4.66

1.64
4.72
P/S 4.55
COV's P/S is ranked higher than
61% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. COV: 4.55 )
COV' s 10-Year P/S Range
Min: 1.23   Max: 4.61
Current: 4.55

1.23
4.61
PFCF 25.84
COV's PFCF is ranked higher than
89% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.06 vs. COV: 25.84 )
COV' s 10-Year PFCF Range
Min: 9.51   Max: 362.56
Current: 25.84

9.51
362.56
POCF 21.73
COV's POCF is ranked higher than
78% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.84 vs. COV: 21.73 )
COV' s 10-Year POCF Range
Min: 7.39   Max: 39.39
Current: 21.73

7.39
39.39
EV-to-EBIT 23.50
COV's EV-to-EBIT is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.15 vs. COV: 23.50 )
COV' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 76.1
Current: 23.5

6.7
76.1
PEG 13.70
COV's PEG is ranked higher than
84% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. COV: 13.70 )
COV' s 10-Year PEG Range
Min: 0.41   Max: 8.57
Current: 13.7

0.41
8.57
Shiller P/E 30.67
COV's Shiller P/E is ranked higher than
90% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 168.61 vs. COV: 30.67 )
COV' s 10-Year Shiller P/E Range
Min: 17.76   Max: 30.88
Current: 30.67

17.76
30.88
Current Ratio 1.92
COV's Current Ratio is ranked higher than
62% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. COV: 1.92 )
COV' s 10-Year Current Ratio Range
Min: 0.89   Max: 2.85
Current: 1.92

0.89
2.85
Quick Ratio 1.43
COV's Quick Ratio is ranked higher than
64% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. COV: 1.43 )
COV' s 10-Year Quick Ratio Range
Min: 0.73   Max: 2.17
Current: 1.43

0.73
2.17
Days Inventory 119.42
COV's Days Inventory is ranked higher than
73% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.27 vs. COV: 119.42 )
COV' s 10-Year Days Inventory Range
Min: 44.38   Max: 152.01
Current: 119.42

44.38
152.01
Days Sales Outstanding 49.47
COV's Days Sales Outstanding is ranked higher than
88% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.40 vs. COV: 49.47 )
COV' s 10-Year Days Sales Outstanding Range
Min: 52.46   Max: 63.06
Current: 49.47

52.46
63.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
COV's Dividend Yield is ranked lower than
52% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.31 vs. COV: 1.30 )
COV' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.51
Current: 1.3

0.39
2.51
Dividend Payout 0.43
COV's Dividend Payout is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. COV: 0.43 )
COV' s 10-Year Dividend Payout Range
Min: 0.19   Max: 1.43
Current: 0.43

0.19
1.43
Dividend growth (3y) 39.80
COV's Dividend growth (3y) is ranked higher than
97% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. COV: 39.80 )
COV' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 66.6
Current: 39.8

0
66.6
Yield on cost (5-Year) 3.80
COV's Yield on cost (5-Year) is ranked higher than
81% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. COV: 3.80 )
COV' s 10-Year Yield on cost (5-Year) Range
Min: 1.14   Max: 7.33
Current: 3.8

1.14
7.33
Share Buyback Rate 2.80
COV's Share Buyback Rate is ranked higher than
96% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.40 vs. COV: 2.80 )
COV' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.5
Current: 2.8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 4.30
COV's Earnings Yield (Greenblatt) is ranked higher than
80% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. COV: 4.30 )
COV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 15
Current: 4.3

1.3
15
Forward Rate of Return (Yacktman) 6.59
COV's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. COV: 6.59 )
COV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.6   Max: 34.1
Current: 6.59

6.6
34.1

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 10,979 11,379 11,923
EPS($) 4.31 4.69 4.64
EPS without NRI($) 4.31 4.69 4.64

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, TMO, COO, ISRG » details
Traded in other countries:6COP.Germany,
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.
» More Articles for COV

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 02 2015 
Dravid Abrams and His Top Four Stock Picks Jan 27 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 17 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Abbott: A Brighter Future Aug 28 2014 

More From Other Websites
Farallon Capital Increases Position in Covidien Mar 28 2015
Elliott Management exits position in Covidien Mar 04 2015
Chilton Investment Company raises its stake in Covidien plc Feb 24 2015
Strong fiscal third quarter for Medtronic Feb 17 2015
FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral... Feb 12 2015
Boston Scientific reports R&D rebound during solid 2014 Feb 04 2015
Colorado important to an enlarged Medtronic Jan 29 2015
Medtronic completes blockbuster buy of Covidien; both companies big in Colorado Jan 27 2015
With Covidien-Medtronic merger final, attention turns to cost-cutting Jan 27 2015
COVIDIEN PLC Files SEC form 8-K, Change in Directors or Principal Officers Jan 27 2015
Medtronic Completes Acquisition of Covidien Jan 26 2015
Covidien Announces Effectiveness of Medtronic Transaction Scheme of Arrangement Jan 26 2015
Covidien Announces Effectiveness of Medtronic Transaction Scheme of Arrangement Jan 26 2015
Covidien Announces Effectiveness of Medtronic Transaction Scheme of Arrangement Jan 26 2015
Medtronic's Pending Acquisition of Covidien Approved by Irish High Court Jan 26 2015
Medtronic's Pending Acquisition of Covidien Approved by Irish High Court Jan 26 2015
10-Q for Covidien Plc Jan 25 2015
COVIDIEN PLC Files SEC form 10-Q, Quarterly Report Jan 23 2015
Covidien beats before buyout Jan 22 2015
Covidien Supports Retreat & Refresh Stroke Camp for Stroke Survivors and Caregivers Jan 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK